As of 18 Sept 2026, Nath Bio-Genes (India) Ltd share price is ₹147.90. The stock opened at ₹147.90 and had closed at ₹146.00 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹126.75 and a high of ₹207.00. In terms of performance, Nath Bio-Genes (India) Ltd share price has increased by 1.74% over the past six months and has decreased by 11.73% over the last year.
NATHBIOGEN Stock Price Chart
Nath Bio-Genes (India) Ltd Overview
About NATHBIOGEN
Nath Bio-Genes (India) engaged in the business of research, development, production, processing and marketing of hybrid and varietal seeds for field crops and vegetables, catering to the agricultural needs of farmers across India and international markets
Nath Bio-Genes (India) Ltd Historical Performance
Nath Bio-Genes (India) Ltd Fundamentals
Nath Bio-Genes (India) Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 439.41 | 367.04 | 333.27 | 301.85 | 280.21 |
| EBITDA | 66.36 | 57.56 | 51.03 | 49.45 | -49.53 |
| Net Profit | 44.43 | 42.14 | 40.18 | 35.17 | -67.17 |
| EPS | 23.38 | 22.00 | 21.63 | 18.50 | -35.43 |
Nath Bio-Genes (India) Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 145.33 |
| Resistance 1 (R1) | 147.33 |
| Pivot Point | 146.67 |
Nath Bio-Genes (India) Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 11-Sep-2026 | 04-May-2026 | 11-Sep-2026 | Final | ₹2.00 |
| 14-Aug-2025 | 29-Apr-2025 | 14-Aug-2025 | Final | ₹2.00 |
| 09-Aug-2024 | 08-May-2024 | 09-Aug-2024 | Final | ₹2.00 |
| 04-Jul-2023 | 22-Apr-2023 | 30-Jun-2023 | Final | ₹2.00 |
| 23-Jun-2022 | 30-May-2022 | 25-Jun-2022 | Final | ₹2.00 |
NATHBIOGEN Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Satish Kagliwal | Chairman & Managing Director |
| Akash Kagliwal | Non Executive Director |
| Jeevanlata Kagliwal | Executive Directorector |
Nath Bio-Genes (India) Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Hindustan Unilever LtdHINDUNILVR | ₹1,949.00-0.66% | ₹5,31,630.27 | 36.57 | 22.41% |
| ITC LtdITC | ₹265.20+0.40% | ₹3,90,911.96 | 11.06 | 28.53% |
| Nestle India LtdNESTLEIND | ₹1,377.40-0.51% | ₹2,39,998 | 73.60 | 67.85% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Nath Bio-Genes (India) Ltd today is ₹147.90 on NSE and ₹147.90 on BSE.
- The 52-week high of Nath Bio-Genes (India) Ltd is ₹207.00, while the 52-week low is ₹126.75.
- The current market capitalisation of Nath Bio-Genes (India) Ltd is approximately ₹277 crore.
- The P/E (Price-to-Earnings) ratio of Nath Bio-Genes (India) Ltd is 5.89. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Nath Bio-Genes (India) Ltd is 0.39. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Nath Bio-Genes (India) Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for NATHBIOGEN on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Nath Bio-Genes (India) Ltd has delivered a return of approximately -34.63%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Nath Bio-Genes (India) Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 45.60% promoters, 0.25% FIIs, 0.01% DIIs, and 34.37% public shareholders.

